查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750662

美国介入性心臟病学和周边血管市场：市场规模、份额、趋势分析（按产品和应用）、细分市场预测（2025-2030 年）

U.S. Interventional Cardiology And Peripheral Market Size, Share & Trends Analysis Report By Product, By Application, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 160 Pages | 商品交期: 2-10个工作天内

价格

美国介入性心臟病学和周边血管市场的成长和趋势：

根据Grand View Research, Inc.的最新报告，美国介入性心臟病学和周边血管市场规模预计到2030年将达到111.9亿美元，预测期内的复合年增长率为6.0%。

心血管和周边血管疾病负担的不断加重、人们对微创手术的日益偏好以及设备技术的不断进步，共同推动市场的发展。老年人口的不断增长、糖尿病和高血压盛行率的不断上升以及支持性报销政策的不断出台，进一步推动了市场的成长。

心血管疾病的日益普及推动了介入性心臟病学和周边血管市场的持续成长。许多患者在不同阶段被诊断出患有冠状动脉和周边动脉阻塞，促使他们及时接受医疗干预。随着诊断技术的进步和定期筛检，疾病检测能力不断提升，治疗重点正转向更早、侵入性更低的治疗途径。

血管成形术、支架置入术和血栓切除术等介入性手术如今已成为有效管理这些疾病的核心手段。美国疾病管制与预防中心（CDC）于2024年10月报告称，心臟病仍然是美国最大的死亡原因，2022年死亡人数达702,880人，相当于五分之一的死亡病例。冠状动脉疾病（CAD）是最常见的疾病，造成超过371,000人死亡。高血压、高胆固醇、吸烟、糖尿病、肥胖和缺乏运动等风险因素被认为是主要原因。

美国介入性心臟病学和周边血管市场：概述

  • 按产品划分，冠状动脉支架部分预计在 2024 年占据最大的收入份额，达到 41.5%。
  • 该领域的成长得益于经皮冠状动脉介入治疗 (PCI) 的日益普及、药物释放型支架技术的持续进步以及美国支持微创心血管手术的优惠报销政策。
  • 根据应用，血管成形术部分将在 2024 年占据最大的收益占有率，为 59.2%。此部分的显着成长主要得益于动脉粥状硬化性心血管疾病的高盛行率、药物释放型球囊支架的使用增加以及对微创血管重组手术的需求不断增长。
  • 新兴企业正在采取多种策略，例如推出新产品来加强其市场地位。
  • 2024年2月，Biotronic在美国推出了Micro Rx导管，支援PCI期间的导管导引线手术。

目录

第一章 分析方法与范围

第二章执行摘要

第三章美国介入性心臟病学和周边血管市场：驱动因素、趋势和范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 美国介入性心臟病学和周边血管市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章美国介入性心臟病学和周边血管市场：按产品分類的估计和趋势分析

  • 产品细分仪表板
  • 美国介入性心臟病学和周边血管市场：按产品分類的差异分析
  • 美国介入性心臟病学和周边血管市场规模和趋势分析（按产品）（2018-2030）
  • 干涉导管
  • 微导管
    • 微导管支援
    • 输送微导管
    • 其他的
  • 导管导引线
  • 外周支架
    • 自膨胀
    • 球囊扩张
    • 药物释放型支架
  • 冠状动脉支架
    • 生物可吸收支架
    • 药物释放型支架
    • 裸金属支架
  • PTCA球囊导管
  • 动脉粥状硬化斑块切除设备
  • 慢性完全闭塞装置
  • 合成外科移植物
  • 栓塞保护装置
  • 下腔静脉过滤器
  • PTA球囊导管
  • 血栓除去装置

第五章美国介入性心臟病学和周边血管市场：应用预测和趋势分析

  • 应用程式细分仪表板
  • 美国介入性心臟病学和周边血管市场：应用差异分析
  • 美国介入性心臟病学及週边血管市场规模及应用趋势分析（2018-2030）
  • 血管成形术
  • 先天性心臟疾病的矫正
  • 血栓切除术
  • 瓣环成形手术
  • 经皮瓣膜修復
  • 其他的

第六章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要企业热力图分析（2024年）
  • 公司简介
    • B. Braun SE
    • BD
    • Cardinal Health
    • Medtronic
    • Teleflex Incorporated
    • WL Gore &Associates Inc.
    • Cook
    • Boston Scientific Corporation
    • AngioDynamics
    • Abbott
    • OrbusNeich Medical Group Holdings Limited
Product Code: GVR-4-68040-581-2

U.S. Interventional Cardiology and Peripheral Market Growth & Trends:

The U.S. interventional cardiology and peripheral market size is anticipated to reach USD 11.19 billion by 2030, growing at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growing burden of cardiovascular & peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology. Increasing geriatric population, higher rates of diabetes & hypertension, and supportive reimbursement policies further fuel market expansion.

The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.

Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.

U.S. Interventional Cardiology And Peripheral Market Report Highlights:

  • Based on product, the coronary stents segment accounted for the largest revenue share of 41.5% in 2024.
  • The segment growth is driven by increasing adoption of Percutaneous Coronary Interventions (PCI), continuous advancements in drug-eluting stent technologies, and favorable reimbursement policies supporting minimally invasive cardiovascular procedures in the U.S.
  • Based on application, the angioplasty segment accounted for the largest revenue share of 59.2% in 2024. The significant growth of this segment is largely driven by the high prevalence of atherosclerotic cardiovascular disease, increasing use of drug-eluting balloons & stents, and rising demand for minimally invasive revascularization procedures.
  • Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.
  • In February 2024, Biotronik launched the Micro Rx catheter in the U.S. to support guidewire procedures during PCI, reflecting ongoing technological progress and sustained market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Interventional Cardiology and Peripheral Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Interventional Cardiology and Peripheral Market: Product Movement Analysis
  • 4.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Interventional Catheters
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Microcatheters
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Support Microcatheters
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Delivery Microcatheters
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Guidewires
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Peripheral Stents
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. Self-Expanding
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Balloon-Expandable
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.4. Drug-Eluting Stents
      • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Coronary Stents
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.2. Bioabsorbable Stents
      • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.3. Drug Eluting Stents
      • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.4. Bare Metal Stents
      • 4.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. PTCA Balloon Catheters
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Atherectomy Devices
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Chronic Total Occlusion Devices
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Synthetic Surgical Grafts
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Embolic Protection Devices
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. IVC Filters
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.15. PTA Balloon Catheters
    • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.16. Thrombectomy Devices
    • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. Interventional Cardiology and Peripheral Market: Application Movement Analysis
  • 5.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Angioplasty
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Congenital Heart Defect Correction
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Thrombectomy
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Valvuloplasty
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Percutaneous Valve Repair
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Key company heat map analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. B. Braun SE
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Product benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. BD
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Product benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Cardinal Health
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Product benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Medtronic
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Product benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Teleflex Incorporated
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Product benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. W. L. Gore & Associates Inc.
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Product benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Cook
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Product benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Boston Scientific Corporation
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Product benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. AngioDynamics
      • 6.4.9.1. Company overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Product benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Abbott
      • 6.4.10.1. Company overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Product benchmarking
      • 6.4.10.4. Strategic initiatives
    • 6.4.11. OrbusNeich Medical Group Holdings Limited
      • 6.4.11.1. Company overview
      • 6.4.11.2. Financial performance
      • 6.4.11.3. Product benchmarking
      • 6.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. interventional cardiology and peripheral market, by region, 2018 - 2030 (USD Million)
  • Table 3 U.S. interventional cardiology and peripheral market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. interventional cardiology and peripheral market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. interventional cardiology and peripheral market: market outlook
  • Fig. 10 U.S. interventional cardiology and peripheral competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. interventional cardiology and peripheral market driver impact
  • Fig. 16 U.S. interventional cardiology and peripheral market restraint impact
  • Fig. 17 U.S. interventional cardiology and peripheral market strategic initiatives analysis
  • Fig. 18 U.S. interventional cardiology and peripheral market: Product movement analysis
  • Fig. 19 U.S. interventional cardiology and peripheral market: Product outlook and key takeaways
  • Fig. 20 Interventional catheters estimates and forecast, 2018 - 2030
  • Fig. 21 Microcatheters estimates and forecast, 2018 - 2030
  • Fig. 22 Support microcatheters estimates and forecast, 2018 - 2030
  • Fig. 23 Delivery microcatheters estimates and forecast, 2018 - 2030
  • Fig. 24 Others estimates and forecast, 2018 - 2030
  • Fig. 25 Guidewires estimates and forecast, 2018 - 2030
  • Fig. 26 Peripheral stents estimates and forecast, 2018 - 2030
  • Fig. 27 Self-expanding estimates and forecast, 2018 - 2030
  • Fig. 28 Balloon-expandable estimates and forecast, 2018 - 2030
  • Fig. 29 Drug-eluting stents estimates and forecast, 2018 - 2030
  • Fig. 30 Coronary stents estimates and forecast, 2018 - 2030
  • Fig. 31 Bioabsorbable stents estimates and forecast, 2018 - 2030
  • Fig. 32 Drug eluting stents estimates and forecast, 2018 - 2030
  • Fig. 33 Bare metal stents estimates and forecast, 2018 - 2030
  • Fig. 34 PTCA balloon catheters estimates and forecast, 2018 - 2030
  • Fig. 35 Atherectomy devices estimates and forecast, 2018 - 2030
  • Fig. 36 Chronic total occlusion devices estimates and forecast, 2018 - 2030
  • Fig. 37 Synthetic surgical grafts estimates and forecast, 2018 - 2030
  • Fig. 38 Embolic protection devices estimates and forecast, 2018 - 2030
  • Fig. 39 IVC filters estimates and forecast, 2018 - 2030
  • Fig. 40 PTA balloon catheters estimates and forecast, 2018 - 2030
  • Fig. 41 Thrombectomy devices estimates and forecast, 2018 - 2030
  • Fig. 42 U.S. interventional cardiology and peripheral market: Application movement analysis
  • Fig. 43 U.S. interventional cardiology and peripheral market: Application outlook and key takeaways
  • Fig. 44 Angioplasty estimates and forecast, 2018 - 2030
  • Fig. 45 Congenital heart defect correction estimates and forecast, 2018 - 2030
  • Fig. 46 Thrombectomy estimates and forecast, 2018 - 2030
  • Fig. 47 Valvuloplasty estimates and forecast, 2018 - 2030
  • Fig. 48 Percutaneous valve repair estimates and forecast, 2018 - 2030
  • Fig. 49 Others estimates and forecast, 2018 - 2030